JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
News|Articles|April 21, 2025
Top 5 recent updates in fertility research
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
Find out the top 5 latest updates and headlines in fertility research in honor of National Infertility Awareness Week (April 20-26, 2025).
Advertisement
Advertisement
As we recognize National Infertility Awareness Week (April 20-26, 2025), it’s an important time to reflect on the innovations, research, and evolving care strategies that are shaping the future of fertility treatment. From clinical breakthroughs to regulatory milestones, the first few months of 2025 have brought encouraging news for patients, providers, and advocates alike, particularly in the areas of in vitro fertilization (IVF), embryo transfer, and reproductive mental health.
Related to this article
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.
A systematic review found transdermal nitroglycerin may modestly reduce hot flashes, but evidence remains limited.
The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.
The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
Advertisement
Advertisement